US Patent Issued to Actinium Pharmaceuticals on Sept. 1 for "DR5 radioimmunotherapy in the treatment of solid cancers" (New Jersey, New York Inventors)

ALEXANDRIA, Va., Sept. 1 -- United States Patent no. 12,721,913, issued on Sept. 1, was assigned to Actinium Pharmaceuticals Inc. (New York).

"DR5 radioimmunotherapy in the treatment of solid cancers" was invented by Dale Ludwig (Rockaway, N.J.) and Eileen Geoghegan (Mamaroneck, N.Y.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Methods for treating a proliferative disease or disorder by administering an antibody radio-conjugate alone or in combination with an immune checkpoint therapy such as an antibody against an immune checkpoint inhibitor, and/or a DNA damage response inhibitor. The proliferative disease or disorder may be a solid cancer, such as breast cancer, ovarian cancer, or prostate cancer."

The...